ABSTRACT
A large majority of early pregnancy losses are the consequence of chromosomal abnormalities of the conceptus. Preimplantation genetic testing for aneuploidy (PGT-A) utilizes trophectoderm biopsy and next-generation sequencing in an attempt to detect embryonic aneuploidy in a trophectoderm biopsy obtained at the blastocyst stage. Y. Verlinsky and A. Kuliev initially proposed what was previously called preimplantation genetic screening by polar body biopsy under the hypothesis that removing aneuploid embryos prior to embryo transfer would improve implantation, pregnancy, and live birth rates for the remaining embryos. Although in most couples with recurrent pregnancy loss subfertility is not a problem, assisted reproductive technology with PGT-A is often advised despite the absence of any supportive evidence. Patients might be interested in PGT-A to shorten the time to conceive, improve reproductive outcome, and reduce miscarriage rate, but to date PGT-A has not shown any benefit in any of these parameters.
